We are live on ! Find out more
ABCL icon

AbCellera Biologics
ABCL

146 hedge funds and large institutions have $338M invested in AbCellera Biologics in 2024 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 37 increasing their positions, 47 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% less call options, than puts

Call options by funds: $1.08M | Put options by funds: $1.16M

2.46% less ownership

Funds ownership: 41.3% → 38.84% (-2.5%)

5% less funds holding

Funds holding: 154 → 146 (-8)

21% less repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 47

23% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 26

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

38% less capital invested

Capital invested by funds: $547M → $338M (-$209M)

Holders
146
Holders Change
-8
Holders Change %
-5.19%
% of All Funds
2.11%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
20
Increased
37
Reduced
47
Closed
26
Calls
$1.08M
Puts
$1.16M
Net Calls
-$73K
Net Calls Change
+$784K

Top Buyers

1
UBS AM
UBS AM
Illinois
+$17.4M
2
Citadel Advisors
Citadel Advisors
Florida
+$2.68M
3
Two Sigma Investments
Two Sigma Investments
New York
+$2.2M
4
PM
Prosight Management
Texas
+$2.13M
5
EAM
Exome Asset Management
New York
+$1.95M

Top Sellers

1
Capital World Investors
Capital World Investors
California
-$11.5M
2
CC
Casdin Capital
New York
-$10.7M
3
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
-$4.8M
4
Lazard Asset Management
Lazard Asset Management
New York
-$3.51M
5
Man Group
Man Group
United Kingdom
-$3.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Royal Bank of Canada
26
Royal Bank of Canada
Ontario, Canada
$1.21M +$62.5K +16,517 +4%
FFGM
27
Founders Fund Growth Management
California
$1.2M – – –
JP Morgan Chase
28
JP Morgan Chase
New York
$989K -$138K -36,501 -10%
State Street
29
State Street
Massachusetts
$943K -$498K -131,705 -29%
Geode Capital Management
30
Geode Capital Management
Massachusetts
$932K +$218K +57,500 +22%
CFG
31
Citizens Financial Group
Rhode Island
$923K +$1.18M +311,890 New
Skandinaviska Enskilda Banken (SEB)
32
Skandinaviska Enskilda Banken (SEB)
Sweden
$913K +$598K +158,000 +105%
Ameriprise
33
Ameriprise
Minnesota
$858K – – –
BC
34
Belmont Capital
California
$770K – – –
COPPSERS
35
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$741K – – –
Susquehanna International Group
36
Susquehanna International Group
Pennsylvania
$736K +$101K +26,690 +12%
PP
37
PDT Partners
New York
$705K -$35.2K -9,290 -4%
Tudor Investment Corp
38
Tudor Investment Corp
Connecticut
$700K +$552K +145,915 +161%
TWC
39
TD Waterhouse Canada
Ontario, Canada
$681K -$48.1K -12,718 -5%
OM
40
Opaleye Management
Massachusetts
$592K +$757K +200,000 New
Dimensional Fund Advisors
41
Dimensional Fund Advisors
Texas
$532K +$5.01K +1,325 +0.7%
P8IP
42
Pier 88 Investment Partners
California
$478K +$479K +126,640 +362%
Jane Street
43
Jane Street
New York
$458K +$211K +55,887 +57%
DFCM
44
Dark Forest Capital Management
Puerto Rico
$432K +$173K +45,721 +46%
SA
45
Sanctuary Advisors
Indiana
$398K +$401K +105,924 New
PCM
46
Prelude Capital Management
New York
$358K +$457K +120,900 New
Fidelity International
47
Fidelity International
Bermuda
$355K +$208K +54,893 +84%
Macquarie Group
48
Macquarie Group
Australia
$353K – – –
PAMP
49
Polar Asset Management Partners
Ontario, Canada
$349K – – –
American Century Companies
50
American Century Companies
Missouri
$347K -$409 -108 -0.1%
1
2
3 4 5

ABCL Hedge Fund Activity: Q2 2024 in Review

146 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q2 2024, worth a combined $338M — down 38% from $547M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of ABCL and 20 opened new positions — a net loss of 6 holders — while 47 trimmed existing stakes and 37 added.

The largest buyer was UBS AM, opening a new position worth an estimated $17.4M. The largest seller was Capital World Investors, cutting an estimated $11.5M.

  • 146 institutional investors held AbCellera Biologics (ABCL) as of Q2 2024, down from 154 in Q1 2024.
  • Funds reported $338M of AbCellera Biologics stock for Q2 2024, down 38% quarter-over-quarter.
  • 20 funds opened new AbCellera Biologics positions in Q2 2024 and 26 closed out, a net change of -6 holders.
  • The largest AbCellera Biologics buyer in Q2 2024 was UBS AM, an estimated $17.4M added.
  • The largest AbCellera Biologics seller in Q2 2024 was Capital World Investors, an estimated $11.5M sold.

Based on aggregated 13F filings for Q2 2024.